Suppr超能文献

胃肠道癌症患者中PD-1配体的分析:聚焦癌症免疫

Analysis of the PD-1 Ligands Among Gastrointestinal Cancer Patients: Focus on Cancer Immunity.

作者信息

Dai Lin, Huang Zilin, Li Wang

机构信息

Cancer Prevention Center, Sun Yat-sen University Cancer Center, Guangzhou, China.

State Key Laboratory of Oncology in South China, Guangzhou, China.

出版信息

Front Oncol. 2021 Mar 23;11:637015. doi: 10.3389/fonc.2021.637015. eCollection 2021.

Abstract

Many types of gastrointestinal cancer have shown promising outcomes after checkpoint blockade immunotherapy; however, it remains largely unclear about the expression profiles of programmed death 1 (PD-1) ligands (CD274 and PDCD1LG2) in the context of human pan-cancer. This work comprehensively analyzed the expression pattern of the PD-1 ligands and the clinical significance in the prognosis prediction among the seven types of gastrointestinal malignancies collected from The Cancer Genome Atlas (TCGA) and the Cancer Cell Line Encyclopedia (CCLE) database. Furthermore, the correlation of CD274/PDCD1LG2 with cancer immunity was also explored. The patients with liver hepatocellular carcinoma (LIHC) receiving cytokine-induced killer (CIK) cell immunotherapy at our cancer center were enrolled. CD274 and PDCD1LG2 displayed inconsistent gene expression levels among the diverse cancer cell lines. Typically, the abnormal expression level of CD274 and PDCD1LG2 was detected in both esophageal carcinoma (ESCA) and stomach adenocarcinoma (STAD), where PDCD1LG2 was related to the overall survival (OS) of the patients in ESCA ( = 0.015) and STAD ( = 0.025). High-serum CD274 and PDCD1LG2 levels predicted a worse survival in the patients with LIHC receiving CIK therapy. More importantly, the expression level of CD274 and PDCD1LG2 was significantly correlated with the degree of Estimation of STromal and Immune cells in MAlignant Tumor tissues using the Expression data (ESTIMATE). In addition, we found that CD274 and PDCD1LG2 were correlated with gene markers in tumor-infiltrating immune cells. Furthermore, the expression of CD274 and PDCD1LG2 was correlated with tumor mutation burden (TMB), microsatellite instability (MSI), mismatch repair (MMR), and DNA methyltransferase (DNMT) of different types of cancers. The present work comprehensively analyzed a RNA sequencing of the PD-1 ligands across the seven distinct types of gastrointestinal cancers, which provided clues for further studies in cancer immunity and development.

摘要

许多类型的胃肠道癌在检查点阻断免疫治疗后已显示出良好的疗效;然而,在人类泛癌背景下,程序性死亡1(PD-1)配体(CD274和PDCD1LG2)的表达谱仍 largely不清楚。这项工作全面分析了从癌症基因组图谱(TCGA)和癌细胞系百科全书(CCLE)数据库收集的七种胃肠道恶性肿瘤中PD-1配体的表达模式及其在预后预测中的临床意义。此外,还探讨了CD274/PDCD1LG2与癌症免疫的相关性。纳入了在我们癌症中心接受细胞因子诱导的杀伤(CIK)细胞免疫治疗的肝细胞癌(LIHC)患者。CD274和PDCD1LG2在不同癌细胞系中的基因表达水平不一致。典型的是,在食管癌(ESCA)和胃腺癌(STAD)中均检测到CD274和PDCD1LG2的异常表达水平,其中PDCD1LG2与ESCA患者的总生存期(OS)相关( = 0.015),与STAD患者的总生存期相关( = 0.025)。高血清CD274和PDCD1LG2水平预示着接受CIK治疗的LIHC患者生存期更差。更重要的是,CD274和PDCD1LG2的表达水平与使用表达数据估计恶性肿瘤组织中基质和免疫细胞(ESTIMATE)的程度显著相关。此外,我们发现CD274和PDCD1LG2与肿瘤浸润免疫细胞中的基因标志物相关。此外,CD274和PDCD1LG2的表达与不同类型癌症的肿瘤突变负担(TMB)、微卫星不稳定性(MSI)、错配修复(MMR)和DNA甲基转移酶(DNMT)相关。目前的工作全面分析了七种不同类型胃肠道癌中PD-1配体的RNA测序,为癌症免疫和发展的进一步研究提供了线索。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df34/8021907/350ec6f7459a/fonc-11-637015-g0001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验